Technical Analysis for WVE - WAVE Life Sciences Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Historical WVE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bearish Engulfing | Bearish | 0.00% | |
| Stochastic Sell Signal | Bearish | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Weak, Overbought and Reversal Signs | Reversal | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | -3.08% | |
| Pocket Pivot | Bullish Swing Setup | -3.08% | |
| Slingshot Bullish | Bullish Swing Setup | -3.08% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 5% | 3 days ago |
| Outside Day | 3 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| 60 Minute Opening Range Breakdown | 3 days ago |
| Down 3% | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2021
WAVE Life Sciences Ltd. Description
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company was founded in 2012 and is based in Singapore.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Rare Diseases Dysfunction Medical Genetics Inflammatory Bowel Disease Dystrophy Muscular Dystrophy Huntington's Disease Genodermatoses Duchenne Muscular Dystrophy Duchenne Genetic Genealogy Epidermolysis Bullosa Cytoskeleton Dystrophin SNP
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.98 |
| 52 Week Low | 4.82 |
| Average Volume | 781,796 |
| 200-Day Moving Average | 8.83 |
| 50-Day Moving Average | 6.41 |
| 20-Day Moving Average | 6.83 |
| 10-Day Moving Average | 7.03 |
| Average True Range | 0.42 |
| ADX | 23.53 |
| +DI | 22.14 |
| -DI | 13.15 |
| Chandelier Exit (Long, 3 ATRs) | 6.29 |
| Chandelier Exit (Short, 3 ATRs) | 6.72 |
| Upper Bollinger Bands | 7.48 |
| Lower Bollinger Band | 6.18 |
| Percent B (%b) | 0.82 |
| BandWidth | 19.07 |
| MACD Line | 0.22 |
| MACD Signal Line | 0.14 |
| MACD Histogram | 0.0759 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.98 | ||||
| Resistance 3 (R3) | 8.00 | 7.77 | 7.85 | ||
| Resistance 2 (R2) | 7.77 | 7.59 | 7.76 | 7.81 | |
| Resistance 1 (R1) | 7.51 | 7.47 | 7.40 | 7.49 | 7.77 |
| Pivot Point | 7.28 | 7.28 | 7.23 | 7.27 | 7.28 |
| Support 1 (S1) | 7.02 | 7.10 | 6.91 | 7.00 | 6.71 |
| Support 2 (S2) | 6.79 | 6.98 | 6.78 | 6.67 | |
| Support 3 (S3) | 6.53 | 6.79 | 6.63 | ||
| Support 4 (S4) | 6.51 |
